OncoMatch/Clinical Trials/NCT06783140
Study of NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Pancreatic Cancer
Is NCT06783140 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2/3 trial studies multiple treatments including Nab paclitaxel and Gemcitabine for pancreatic cancer, advanced or metastatic.
Treatment: Nab paclitaxel · Gemcitabine · Cisplatin — This study will compare two different regimens for patients with BRCA1/2 or PALB2 mutated metastatic pancreatic cancer after progression on first-line FOLFIRINOX.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Cancer type
Pancreatic Cancer
Biomarker criteria
Required: BRCA1 mutation (somatic or germline)
BRCA1/2 or PALB2 mutation (somatic or germline)
Required: BRCA2 mutation (somatic or germline)
BRCA1/2 or PALB2 mutation (somatic or germline)
Required: PALB2 mutation (somatic or germline)
BRCA1/2 or PALB2 mutation (somatic or germline)
Disease stage
Metastatic disease required
Metastatic pancreatic adenocarcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: FOLFIRINOX or NALIRIFOX (FOLFIRINOX, NALIRIFOX) — first-line for metastatic disease
Clinical or radiographic progression on first-line FOLFIRINOX (or NALIRIFOX) for metastatic disease.
Cannot have received: cisplatin (cisplatin)
Patients may not have received prior cisplatin for their pancreatic cancer in any setting.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06783140 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior cisplatin disqualifies patients from enrollment.
Does this trial require BRCA1?
Yes, BRCA1 mutation (somatic or germline) is a required biomarker for enrollment.
Does this trial require BRCA2?
Yes, BRCA2 mutation (somatic or germline) is a required biomarker for enrollment.
Does this trial require PALB2?
Yes, PALB2 mutation (somatic or germline) is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages